Much of the difficulty in establishing a standard of care for relapsed AML is that the disease is clinically and genomically diverse. Nevertheless, significant progress has been made over the past 12 months with the approval of several agents, and the expectation is that additional therapies will ...
1.Faron announces positive BEXMAB study update. News release. Faron Pharmaceuticals, Ltd. October 11, 2023. Accessed October 11, 2023. 2.A study to assess safety, tolerability and preliminary efficacy of bexmarilimab in...
沈志祥教授和北京大学人民医院刘开彦教授主持了澳大利亚白血病和淋巴瘤研究组(ALLG)Andrew Wei教授的“Era of the new standard of Care and beyondfor AML patient ineligible to Intensive Chemotherapy”主题报告环节。Andrew Wei教授表示,通过VIALE-A及VIALE-C研究,维奈克拉联合阿扎胞苷或地西他滨已经成为不适合强诱导...
as well as transcriptional/epigenetic alterations, all leading to excessive proliferation of malignant blood cells in the bone marrow. Tumor heterogeneity due to the acquisition of new somatic alterations leads to a high rate of resistance to current therapies or reduces the efficacy of hematopoietic...
The investigative combination tamibarotene plus azacitidine (Vidaza) and venetoclax (Venclexta) may be more tolerable than standard-of-care (SOC) azacitidine and venetoclax alone, thus addressing an unmet need in patients with monocytic acute myeloid leukemia (AML) who are unfit for intensive chemot...
All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visitKnow AML. ...
“Our study reveals that a significant portion of these patients at the extremes of older age still derive benefit from the VEN-HMA regimen—which is the standard of care for older AML patients and those who are ineligible to receive intensive chemotherapy,” said Watts in the press releas...
(MDM2i) have been tested in the clinic, for example RG7112 in hematological and solid tumors, with some encouraging, but limited, responses6,7. Nevertheless, in pre-clinical studies, MDM2i cooperated with “standard-of-care” therapies, daunorubicin and cytarabine, to eradicate AML8; and the...
(OS) at time of diagnosis, and the variable genetic characteristics of blast cells limit the efficacy of treatment and the chance of survival (Bhansali et al.2023; Dohner et al.2022; Sasaki et al.2021). The current standard of care options for patients deemed who are not candidates for ...
According to results from the QuANTUM-First, quizartinib significantly improved overall survival vs standard of care in patients with newly diagnosed FLT3 ITD–positive acute myeloid leukemia.